Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01093326 · ClinicalTrials.gov registry record · Phase 2
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
A Phase 2 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 2
- Development phase
- 353
- Enrollment target
NCT01093326: Completed Phase 2 study, sponsored by Actelion.
NCT01093326 is a Phase 2 study that has completed, run by Actelion. The registered enrollment target is 353 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (165% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01093326, a Phase 2 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 353 participants
- Enrollment target
Study Summary
This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
Primary Outcome
ARR is defined as the number of confirmed relapses per year. A relapse is defined as the occurrence of an acute episode of one or more new symptoms, or worsening of existing symptoms of multiple sclerosis (MS), not associated with fever or infection, and lasting for at least 24 hours after a stable period of at least 30 days. A confirmed relapse is a relapse accompanied by an increase from the previous clinically stable assessment (that is, performed at least 30 days after the onset of any previ
Interventions
- DRUG Ponesimod 10 mg
- DRUG Ponesimod 20 mg
- DRUG Ponesimod 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2010-05-12 |
| Est. Completion | 2023-09-06 |
| Phase | Phase 2 |
What the finished NCT01093326 record still lists
NCT01093326 is an interventional study that assigns participants to a tested intervention. The registered 353 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (165% higher).
The record links to 0 conditions, and to 3 interventions - of which Ponesimod 10 mg is the first listed.
NCT01093326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01093326 about?
NCT01093326 is a clinical study titled "Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis". This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
What is the current status of trial NCT01093326?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 353 participants. The study started on 2010-05-12. Estimated completion is 2023-09-06.
What interventions are being tested in trial NCT01093326?
The interventions under investigation include: Ponesimod 10 mg (DRUG), Ponesimod 20 mg (DRUG), Ponesimod 40 mg (DRUG).
Who is sponsoring clinical trial NCT01093326?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01093326's enrollment target sits among peer trials
353 129th of 2000 higher than 1,871 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05548296 · 353 participants · Phase 2
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- NCT05884775 · 353 participants · NA
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI